AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 141 min read$HTFL

Farquhar John C.M. sold $1.9M of HTFL

Farquhar John C.M. (Chief Executive Officer) sold 38,900 shares of Heartflow, Inc. (HTFL) at $49.57 ($1.93M total) on 2026-10-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Farquhar John C.M.
Published Oct 14, 2026, 10:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 10:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$HTFL
Bearish
medium confidence
Mentioned
$HTFL
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HTFLBearishLow
01

Why it matters

The filing provides fresh, material information about insider holdings, which can influence short‑term sentiment.

02

Market read

First‑report insider sale by the CEO, modest size, may cause slight negative bias in HTFL trading.

03

What to watch

Potential upcoming clinical data or partnership news could offset the sell‑off pressure.

Relevance 5/10Novelty 6/10Timing: post‑market 2026‑10‑14

Background

SEC Form 4 filing discloses an insider transaction by Heartflow's CEO.

Company-level read

Ticker impact

$HTFLBearishMedium confidence
Context

CEO Farquhar sold 38,900 shares at $49.568 each, total $1.93M, reducing his stake to 283,014 shares.

Expected impact

likely pressure as the market prices in the insider sell.

Evidence & confidence

A $1.9M open‑market sale by the chief executive is material but not large enough to trigger a sharp move; traders may watch for further insider activity.

Market effects

Sector

Minimal impact on the broader medical‑device sector; the sale is company‑specific.

Regional

U.S. market only; no regional ripple effect.

Global

Low; limited to investors tracking HTFL.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to fundamentals; price may remain stable.

Key entities

  • company
    Heartflow, Inc.

    Medical‑device firm listed on NASDAQ (HTFL).

  • person
    Farquhar John C.M.

    Chief Executive Officer of Heartflow.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

HTFL insider trading history →

Related articles

SEP 13
$HTFLHigh

HTFL Soars After Q2 Beat And Raised 2026 Revenue Outlook

HeartFlow (HTFL) stock rose 9.63% after Q2 earnings beat and raised 2026 revenue outlook. Q2 revenue was $64.08M with 80.1% gross margin, but -55.8% profit margin. Company has strong liquidity with $162.55M cash and low debt. Analysts see near-term support at $46-$47 and resistance at $54-$56, with a 12-month target of $60 if growth continues.

timothysykes.com2 min
AUG 19
$HTFLMedAI 8/10

Why Heartflow Stock Soared Today

HeartFlow (HTFL) shares rose after the company raised its full-year revenue targets. Revenue grew 48% YoY to $64.1M in Q2, with adjusted gross margin increasing to 83.3%. The company now expects 40-42% revenue growth for 2026, up from prior forecasts. CEO John Farquhar cited improved operating leverage and scalability.

aol.com2 min